|
USP42 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.99440505513849E-15 |
| Normal-vs-Stage2 |
1.67409999973778E-07 |
| Normal-vs-Stage3 |
1.66644475996236E-13 |
| Normal-vs-Stage4 |
2.92432744686266E-13 |
| Stage1-vs-Stage2 |
7.867200E-01 |
| Stage1-vs-Stage3 |
8.071500E-02 |
| Stage1-vs-Stage4 |
1.885700E-02 |
| Stage2-vs-Stage3 |
1.802210E-01 |
| Stage2-vs-Stage4 |
4.171600E-02 |
| Stage3-vs-Stage4 |
3.511200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.171700E-04 |
| Normal-vs-Asian |
7.93790000397365E-09 |
| Caucasian-vs-AfricanAmerican |
4.274800E-01 |
| Caucasian-vs-Asian |
8.201800E-01 |
| AfricanAmerican-vs-Asian |
5.988000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.55111512312578E-16 |
| Normal-vs-Female |
1.62703184258817E-12 |
| Male-vs-Female |
1.224220E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.6716628081781E-12 |
| Normal-vs-Age(41-60Yrs) |
3.79585252119341E-13 |
| Normal-vs-Age(61-80Yrs) |
1.83697501654478E-12 |
| Normal-vs-Age(81-100Yrs) |
2.765200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.158600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.535190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.876200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.984000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.146200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.772600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.84419999999364E-05 |
| Classical-VS-Follicular |
1.961980E-03 |
| Classical-VS-Other |
2.039400E-01 |
| Classical-VS-Normal |
1.81055170855871E-12 |
| Tall-VS-Follicular |
2.326400E-01 |
| Tall-VS-Other |
6.810600E-01 |
| Tall-VS-Normal |
1.74416037168612E-13 |
| Follicular-VS-Other |
8.543600E-01 |
| Follicular-VS-Normal |
2.30770957898585E-12 |
| Other-VS-Normal |
6.559200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.73527858748912E-13 |
| Normal-vs-N1 |
1.85379489536786E-11 |
| N0-vs-N1 |
3.948800E-01 |
|
|
